Who is sponsoring NCT01551719?

NCT01551719 is sponsored by Federico II University.

What drugs are being tested in NCT01551719?

Interventions in NCT01551719: Implemented procedure.

What condition does NCT01551719 study?

NCT01551719 studies Infection of Skin and/or Subcutaneous Tissue.

Is NCT01551719 still recruiting?

NCT01551719 is currently withdrawn. Last updated 28 December 2012.

Last reviewed 2012-12-28 · How we verify

NCT01551719

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Usefulness of Mic/Breakpoint Ratio and Penetration in Tissues. A Prospective Study of Clinical Validation

Withdrawn NA Last updated 28 December 2012

What this trial tests

NA trial testing Implemented procedure in Infection of Skin and/or Subcutaneous Tissue. Withdrawn.

Timeline

1 March 2012

Primary endpoint
1 March 2013

1 March 2013

Quick facts

Lead sponsor	Federico II University
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	non randomized
Design	crossover
Masking	none
Primary purpose	treatment
Start date	1 March 2012
Primary completion	1 March 2013
Estimated completion	1 March 2013
Sites	2 locations across Italy

Drugs / interventions tested

Implemented procedure

Conditions studied

Infection of Skin and/or Subcutaneous Tissue — all drugs for Infection of Skin and/or Subcutaneous Tissue →

Sponsor

Federico II University

Who can join

18 and older, any sex, with Infection of Skin and/or Subcutaneous Tissue. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Complete recovery rate from infection
Time frame: At the end of treatment (an expected average of 10 days)
Complete resolution of fever, leukocytosis, and any local signs of infection

Sponsor's own description

The general objective of the study is to assess whether the implementation of the antibiotic essay with the Breakpoint/MIC ratio and data on penetration of the antibiotic in the site of infection may improve the outcome of infections compared to using only the standard procedures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Federico II University trials

Trials by the same sponsor.

NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01551719 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federico II University
Last refreshed: 28 December 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01551719.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing